Search
Research
The changing epidemiology of invasive pneumococcal diseaseWe investigated trends in invasive pneumococcal disease (IPD) in Western Australia (WA).
Research
TLR2 mediates recognition of live staphylococus epidermidisStaphylococcus epidermidis is a nosocomial pathogen that causes catheter-associated bacteremia in the immunocompromised, including those at the extremes of age
Research
Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infectionsThis review aims to systematically identify and summarise the effects of different antifungal therapies in children with proven, probable or suspected...
Research
Diverging trends for lower respiratory infections in non-Aboriginal and Aboriginal childrenTo investigate temporal trends in admission rates for acute lower respiratory infections (ALRI) in a total population birth cohort of non-Aboriginal and...
Research
Vaccinating young adults against HPV: the importance of understanding health decision-making and behaviourVaccination of young teenage females against human papillomavirus (HPV) with a newly licenced quadrivalent vaccine designed to prevent cervical cancer and...
Research
Heritable and environmental determinants of hospitalisation for common childhood illnessesWe will leverage the unique Western Australian data linkage resources to undertake the definitive twin and sibling study of infection-related hospitalisation
Research
GAMA projectThis study investigated host gene expression in response to new HIV infection.
Research
MeaslesMeasles is a highly contagious infectious disease that can cause severe, long-term complications in children.
Research
Global risk of selection and spread of Plasmodium falciparum histidine-rich protein 2 and 3 gene deletionsSince their first detection in 2010, Plasmodium falciparum malaria parasites lacking the P. falciparum histidine-rich protein 2 gene (pfhrp2) have been observed in 40 of 47 surveyed countries, as documented by the World Health Organization. These genetic deletions reduce detection by the most widely used rapid diagnostic tests, prompting three countries to switch to alternative diagnostics.
Research
Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling studyThe Australian Therapeutic Goods Administration approved the use of nirsevimab, a long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV), in November 2023. Western Australia (WA) implemented a combination of nirsevimab administration strategies designed to protect all infants starting in April 2024, before the epidemic season. We developed a dynamic transmission model to predict the impact of WA's RSV immunisation program on infant hospitalisations.